Many studies have revealed pathways of epigenetic gene silencing by Polycomb repressive complex 2 (PRC2) in vivo, but understanding the underlying molecular mechanisms requires biochemistry. Here we analyze interactions of reconstituted human PRC2 with nucleosome complexes. Histone modifications, the H3K27M cancer mutation, and inclusion of JARID2 or EZH1 in the PRC2 complex have unexpectedly minor effects on PRC2-nucleosome binding. Instead, protein-free linker DNA dominates the PRC2-nucleosome interaction. Specificity for CG-rich sequences is consistent with PRC2 occupying CG-rich DNA in vivo. PRC2 preferentially binds methylated DNA regulated by its AEBP2 subunit, suggesting how DNA and histone methylation collaborate to repress chromatin. We find that RNA, known to inhibit PRC2 activity, is not a methyltransferase inhibitor per se. Instead, RNA sequesters PRC2 from nucleosome substrates, because PRC2 binding requires linker DNA, and RNA and DNA binding are mutually exclusive. Together, we provide a model for PRC2 recruitment and an explanation for how actively transcribed genomic regions bind PRC2 but escape silencing.
PRC2 is a histone methyltransferase that specifically deposits methyl groups onto lysine 27 of histone H3. PRC2 is absolutely required for epigenetic silencing during embryonic development and cancer, and the importance of PRC2 for stem cell renewal and pluripotency is highlighted by the early embryonic lethality of mice with deletions of these genes 1 . In Drosophila, recruitment of Polycomb-group proteins to target genes involves DNA sequences called Polycomb responsive elements (PREs) 2, 3 . However, how PRC2 is recruited to sites of action in mammalian cells has remained poorly understood.
Earlier work has suggested that RNA can contribute to targeting PRC2 to specific genomic loci 4 or to holding it 'poised but in check' 5 . PRC2 clearly interacts with RNA in vitro and in vivo, in both cases binding so many RNAs that its binding could be characterized as promiscuous 6, 7 . Recently, our group demonstrated that PRC2 reads RNA motifs consisting of short repeats of consecutive guanines, which are abundant in the human transcriptome 8 . Although the hidden specificity in promiscuous RNA binding has been revealed, the question of RNA functionality still remains: what role do RNA molecules play in the regulation of PRC2?
Two studies showed that RNA inhibits PRC2 catalytic activity on histone H3K27 (refs. 5,9) . Additional insight came from the Jenner lab members, who concluded via pulldown experiments that purified nuclear RNA antagonizes PRC2 binding to chromatin 10 . Despite being an important initial observation, chromatin includes nucleosomes with different histone modifications, and whether such modifications would counteract RNA inhibition was not explored.
Pre-existing histone modifications have been proposed to be important determinants of PRC2 recruitment to genomic loci. Prior studies have shown that the PRC2 complex reads H3K27me3 marks of repressive chromatin and that binding to these histone modifications stimulates PRC2 enzymatic activity 11 . On the other hand, H3K4me3 and H3K36me3 marks of active chromatin are also recognized by PRC2, and such binding events inhibit PRC2 catalytic activity 12 . A histone-based perspective on PRC2 recruitment is epitomized by studies of pediatric high-grade gliomas that suggested that a H3K27M missense mutation is able to sequester PRC2 and suppress its enzymatic function 13 . Although the equilibrium dissociation constants (K d ) for interaction of various modified histone peptides with PRC2 have been measured 14 , and the binding of modified histone peptides has been visualized at atomic resolution 15 , the nucleosome-binding activity of PRC2 has thus far remained understudied 16 . In addition, knowing the affinity of PRC2 for nucleosomes vis-à-vis RNAs would inform models of PRC2-RNA functionality in mammals.
Here we undertake quantitative binding studies with recombinant PRC2 and reconstituted chromatin with and without RNA. We find that PRC2 binds protein-free nucleosome linkers and prefers GCrich DNA, in agreement with bioinformatics showing PRC2 peaks at CG-rich DNA regions 8, 17 . Remarkably, the intrinsic properties of PRC2-nucleosome interactions provide a straightforward explanation for previously perplexing in vivo observations.
RESULTS

PRC2 binds longer nucleosome arrays with increased affinity
To quantify the binding affinities of human PRC2 with nucleosomes, we assembled 601-positioned mononucleosomes by standard salt gradient dialysis (Supplementary Fig. 1a,b) . The 601-Widom sequence positions the nucleosome symmetrically with a DNA linker at each end 18 . Using EcoRI digestion and atomic-force microscopy (AFM), we verified that nucleosomes were neither under-nor oversaturated with histones ( Fig. 1a and Supplementary Fig. 1c-e ).
We purified a recombinant PRC2 5-mer complex (EZH2−EED− SUZ12−RBBP4−AEBP2) (ref. 6) (Supplementary Fig. 1f,g) . Binding of PRC2 to nucleosomes was measured by an electrophoretic mobility shift assay (EMSA), and the shifted bands were shown to contain PRC2 as well as nucleosomes (Supplementary Fig. 1h ). The apparent dissociation constant (K d app ) for mononucleosomes was 280 ± 19 nM ( Fig. 1b,c ; error defined in figure legend). Notably, this binding is dramatically stronger than the 40-400-µM K d app range measured for PRC2 binding to various H3 peptide substrates 11, 14 .
Previous studies 19, 20 have reported that PRC2 prefers to methylate polynucleosomes over mononucleosomes; here we tested whether this preference might occur at the level of binding. We assembled trinucleosome and dodecanucleosome arrays, both with a linker-DNA length of 60 base pairs (bp). The K d app values of PRC2 for tri-and dodecanucleosomes were 23 ± 9 nM and 9 ± 2 nM, respectively, which are much higher affinities than those measured for mononucleosomes ( Fig. 1b,c) . Notably, we did not adjust these K d app values for the number of binding sites on tri-and dodecanucleosomes; thus, the affinity per nucleosome increased from mono-to trinucleosomes but did not increase further for dodecanucleosomes. In addition, cooperativity increased substantially for PRC2 binding to arrays compared to mononucleosomes (Hill coefficient, Fig. 1c ). Thus, PRC2 prefers binding to tandem nucleosome repeats over mononucleosomes, with trinucleosomes largely achieving optimal affinity and dodecanucleosomes binding most cooperatively.
For our EMSA experiments, the use of controls for protein-free DNA and the PRC2-DNA complex (right-hand lanes of each gel in Fig. 1b ) addressed some potential concerns about the binding studies. Namely, the nucleosomes did not dissociate at the subnanomolar concentrations used in the binding reaction, because protein-free DNA runs distinguishably from nucleosomes on the agarose gel, and no free DNA was observed in the experimental lanes. Alternatively, if nucleosomes unraveled and the released free DNA were then bound by PRC2, the resulting PRC2-DNA complex would have mobility lower than that of the PRC2-nucleosome complexes; but no such PRC2-DNA species was observed in the experimental lanes. The exception is the dodecanucleosomes (Fig. 1b, bottom) , for which half of the DNA was fully assembled and the other half ran as undersaturated arrays. In this case, both the fully assembled and undersaturated arrays were bound by PRC2.
RNA is not an active-site inhibitor of PRC2 methyltransferase
RNA has previously been shown to inhibit PRC2 catalytic activity 5,9 . To quantitatively measure RNA-mediated enzymatic inhibition, PRC2 and in vitro-reconstituted mononucleosomes were incubated with radiolabeled S-adenosylmethionine ( 14 C-SAM) methyl donor, and RNA was titrated into the reaction. (GGAA) 10 RNA (which forms Gquadruplexes) was used for this analysis, owing to its optimal binding, and poly(A) 40 provided a negative control RNA that does not bind PRC2 (refs. 5,8) .
In the absence of RNA, our histone methyltransferase (HMTase) assays revealed the expected methylation of histone H3 (dashed red box, Fig. 1d ). We also observed automethylation of the EZH2 subunit, as has been previously reported by other groups 21, 22 (dashed blue box, Fig. 1d ). The presence of (GGAA) 10 RNA in the HMTase assay dramatically inhibited H3K27 methylation but not EZH2 automethylation ( Fig. 1e) . Poly(A) 40 RNA, which does not bind to PRC2, had no observable inhibitory effects ( Supplementary Fig. 1i ).
It is striking that RNA had only a small effect on EZH2 automethylation, even at the highest RNA concentration tested (60 µM). It is useful to note that an active-site mutation in EZH2 abolishes both automethylation and H3K27 methylation (X.W., R.D.P., Y. Long, A.R.G. and T.R.C., unpublished data), indicating that the methylation of EZH2 is intrinsic and not due to a contaminating protein. Thus, the persistence of automethylation in the presence of RNA indicates that the RNA is not an active-site inhibitor, but it interferes with H3K27 methylation by other means.
One obvious hypothesis for the mechanism of RNA inhibition is that RNA simply disrupts the association of PRC2 with nucleosomes. Therefore, we titrated unlabeled RNA with preformed complexes of PRC2 and radiolabeled trinucleosomes. (GGAA) 10 RNA stripped PRC2 from nucleosomes (Fig. 1f, bottom) . Dissociation was substantially complete at a substoichiometric RNA concentration, consistent with each RNA molecule possibly interacting with two PRC2 complexes. In contrast, poly(A) 40 failed to compete ( Fig. 1f, top) . Together, these data support the conclusion that RNA and nucleosomes share the same or mutually exclusive binding sites for PRC2. These findings are in agreement with a recent study that suggested that the interaction of PRC2 with RNA and chromatin is mutually antagonistic 10 .
Modified histones have small effects on PRC2 binding or RNA inhibition
PRC2 is known to bind the N-terminal tail of H3; it recognizes unmodified H3K27 via the EZH2 subunit, and it binds H3K4me3 and H3K27me3 at allosteric regulatory sites. Accordingly, we hypothesized that the binding of PRC2 to nucleosomes would be significantly affected if the nucleosomes carried these covalent modifications. More specifically, perhaps H3K27me3 histone modifications would counteract the inhibitory effects of RNA. We therefore reconstituted mono-and trinucleosomes containing unmodified H3, H3K4me3, or H3K27me3 modifications ( Supplementary Figs. 2, 3 and 4a). We validated each of the modified nucleosomes with HMTase assays; PRC2 methylated the unmodified H3 nucleosomes but not the H3K27me3 nucleosomes ( Fig. 2a ). Furthermore, as expected, PRC2's catalytic activity was diminished four-fold when nucleosomes contained H3K4me3 active marks ( Fig. 2a) . We also prepared nucleosomes harboring a H3K27M mutation, which is associated with pediatric glioma and thought to sequester PRC2 in vivo owing to a tight binding interaction 13 .
Unexpectedly, PRC2 bound all of these nucleosome variants with similar affinity (Fig. 2b,c) . Unmodified mononucleosomes were bound with K d app = 280 nM, and H3K27me3 nucleosomes and H3K27M nucleosomes were bound only slightly more tightly. H3K4me3 nucleosomes bound to PRC2 with an affinity that was only marginally weakened ( Fig. 2c and Supplementary Fig. 4b ).
Together, these data lead to the unanticipated conclusion that PRC2 binds nucleosomes containing different marks with similar nanomolar affinity.
Given the similar binding by PRC2 measured with modified nucleosomes, we anticipated that RNA would inhibit PRC2 binding to all of these modified nucleosomes. Indeed, we observed that RNA disrupted complexes of PRC2 and H3K27me3, H3K4me3, and H3K27M nucleosomes at similar stoichiometry as observed a r t i c l e s a r t i c l e s previously for unmodified nucleosomes ( Fig. 2d and Supplementary  Fig. 4c ). Therefore, we conclude that histone marks contribute little to the targeting of PRC2 to nucleosomes and do not impact the ability of RNA to sequester PRC2 away from nucleosomes.
Histone-free linker DNA dictates PRC2 binding to nucleosomes
While investigating nucleosome-binding properties, we tested PRC2 binding to control naked DNA templates, expecting the affinities to the DNAs to be markedly weaker than that to their histone-coated counterparts. Surprisingly, the K d app values for PRC2 binding to the various naked DNA templates were all in the nanomolar range ( Fig. 2c and Supplementary Fig. 4d ). More remarkably, PRC2's affinity for assembled mononucleosomes was ten-fold weaker than that for the corresponding protein-free DNA.
The simplest explanation for this unexpected finding is that the histone octamer shields DNA surfaces that PRC2 would otherwise bind. In other words, we surmised that the protein-free linker regions of nucleosomes dictate PRC2 binding. To test this hypothesis, we reconstituted H2B-Cy5-labeled nucleosome core particles (NCPs) using 147-bp template DNA and mononucleosomes using 207-bp DNA (Supplementary Fig. 5a ). Nucleosomes were purified using fast protein liquid chromatography (FPLC) to assure homogeneity ( Supplementary Fig. 5b ). Astonishingly, with the linker DNA absent, PRC2 binding to nucleosomes was attenuated to a micromolar affinity of K d app = 41 ± 15 µM ( Fig. 3a,b ; error defined in figure legend), consistent with the weak binding of PRC2 to histone tails 14 . Yet, robust PRC2 binding to nucleosomes was restored with the addition of linker DNA (Fig. 3a,b ). The strongest binding was observed for protein-free 147-bp DNA ( Fig. 3b and Supplementary Fig. 5c ). These results with H2B-Cy5 fluorescently labeled nucleosomes were confirmed for nucleosomes labeled with 32 P-DNA ( Supplementary Fig. 5d ). 10 RNA inhibits H3K27 methylation. The persistence of EZH2 automethylation signal (blue-dashed box) but not H3K27 methylation signal (red-dashed box) indicates that RNA is not an active-site inhibitor. 14 C-SAM was used as a cofactor. PRC2 and histone proteins were visualized using Coomassie staining (left), and methylation levels were determined by 14 C-autoradiography (right). Data points represent two-fold titrations ranging from 0-60 µM RNA. (e) Quantification of autoradiography gel in d. Data fit with exponential decay curves. Error bars give s.d., n = 3 independent experiments. (f) Preformed PRC2-trinucleosome complexes are disrupted by (GGAA) 10 RNA but not by negative control poly(A) 40 RNA. PRC2-trinucleosome complexes were fully disrupted (red arrow) at a PRC2/RNA molar ratio of ~2:1. Data points represent three-fold titrations ranging from 0-10 µM RNA. In b, d and f, "+" represents presence of the indicated component, and "0" indicates its absence. Uncropped gel images are shown in Supplementary Data Set 1.
a r t i c l e s
Because the lack of PRC2 binding to NCPs was unanticipated, we performed an additional test. We generated NCPs by treating 207-bp mononucleosomes with MNase-ExoIII (ref. 23) , which allowed the same nucleosome preparation to be tested with and without linker DNA. MNase-ExoIII treatment successfully trimmed mononucleosomes to core particles ( Supplementary Fig. 5e ). We found that PRC2 binding to these trimmed NCPs was again attenuated to micromolar affinity ( Supplementary Fig. 5f ).
Given that PRC2 will rarely encounter isolated mononucleosomes in vivo, we proceeded to test whether PRC2 binds linker DNA in a chromatin array. Therefore, we subjected dodecanucleosome arrays to limited MNase digestion with or without PRC2. Typically, limited MNase digestion of nucleosome arrays produces double-stranded breaks within nucleosome linker regions. In the absence of PRC2, a ladder corresponding to the approximate positions of nucleosomes was revealed ( Fig. 3c) . However, as PRC2 was titrated into the reaction, PRC2 binding to DNA linker regions protected the dodecanucleosome arrays against MNase digestion. This is shown by the accumulation of higher-molecular-weight DNA fragments (lanes 4 and 8 of Fig 3c and Supplementary Fig. 6a,b) . Such a protection pattern has been observed for H1, a known linker histone 24 . Therefore, these data support the hypothesis that PRC2 binds linker regions of nucleosome arrays.
PRC2 prefers to bind long-linker dinucleosomes
PRC2 has been reported to occupy both promoter regions and inactive heterochromatin regions. However, these chromatin states may differ in nucleosome spacing and accessible linker DNA. Thus, we asked whether the spacing between two adjacent nucleosomes modulates PRC2 binding and activity. We reconstituted a fluorescent dinucleosome mimetic from a CpG island (CGI) promoter of a PRC2-regulated gene 17 (Supplementary Fig. 7a ) by inserting a 100-bp linker between two 601-positioned nucleosomes. For comparison, we reconstituted dinucleosomes with a 50-or 10-bp linker, with the latter mimicking a gene-body dinucleosome 25, 26 (details of dinucleosome design in Supplementary Fig. 7b,c) . As shown by EMSA, PRC2 preferentially bound to long-linker dinucleosomes ( Fig. 4a,b ). Binding to dinucleosomes with a 10-bp linker was substantially diminished, yet PRC2 still bound with a nanomolar affinity of 276 ± 16 nM. Perhaps nucleosome breathing, the transient unwrapping of DNA from the histone core, could extend a short linker to allow binding of the entire PRC2 complex. Therefore, although PRC2 prefers binding to longer stretches of protein-free DNA, it is clear that PRC2 can still be targeted to more closely packed nucleosomes. Nevertheless, our conclusion still holds that a stretch of accessible DNA allows PRC2 to bind nucleosome substrates optimally. a r t i c l e s
We hypothesized that dinucleosomes with a 100-bp linker length would have the greatest stimulation of HMTase, owing to optimal binding to PRC2. However, PRC2 activity did not increase monotonically with increasing dinucleosome spacing ( Fig. 4c,d) . Rather, there appears to be a 'Goldilocks effect' , with the 50-bp-linker dinucleosome stimulating PRC2 to a greater extent than either the 10-or 100-bplinker dinucleosomes. Perhaps very long linker DNAs position PRC2 too far from its H3 substrate for catalysis to occur.
PRC2 prefers CG-rich DNA and the AEBP2 subunit confers mCpG specificity PRC2 has been broadly observed to localize with CGIs in vivo, and it has been shown that there is a strong correlation between PRC2 occupancy and GC-rich sequences genome-wide 8, 17, 27 . It seemed likely to us that such targeting occurs via PRC2's intrinsic DNA-binding activity. We tested PRC2 binding to (CG) 30 and (TA) 30 dsDNA substrates using fluorescence polarization. PRC2 bound the CG-rich substrate with a substantially lower K d app (Fig. 5a) , in agreement with the previous in vivo observations. Given that 5-methyl-C (mC) is widespread throughout the mammalian genome and found on up to 80% of CpG dinucleotides 28 and that methylation of CGIs near gene promoters is often associated with gene repression 29 , we hypothesized that PRC2 might preferentially bind mCpG sequences. We found that the methylated DNA (mCpG) 24 bound PRC2 with K d app = 11.3 ± 6.2 nM, which is about 50-fold stronger than that to the unmethylated (CpG) 24 substrate (Fig. 5b,c) . A similar strong preference for PRC2 binding to methylated DNA was found for TERT promoter DNA, which contained the eight mCpG dinucleotides found in vivo as determined by bisulfite sequencing analysis (J. Stern et al., University of Colorado Boulder, personal communication).
To determine which subunit could be responsible for recognizing methylated CpG, we focused on AEBP2, which contains three wellconserved C2H2 zinc finger motifs. These motifs have been suggested to specifically recognize mCpG dinucleotides in other proteins 30 . We purified the PRC2(∆AEBP2) 4-mer complex and repeated the binding experiments with the methylated and unmethylated DNA substrates. PRC2(∆AEBP2) lost binding preference for methylated DNA (Fig. 5d) . To further corroborate this result, we introduced point mutations into each of AEBP2's three conserved C2H2 zinc-finger motifs (Supplementary Fig. 8a ) and found that this mutant PRC2-AEBP2 5-mer complex also lost its preference for methylated DNA (Supplementary Fig. 8b) . Together, these data suggest that AEBP2 is a regulator that helps the PRC2 complex read DNA epigenetic marks and that DNA methylation and histone lysine methylation might be mutually reinforcing.
RNA and DNA binding to PRC2 are mutually exclusive
Understanding the importance of linker-DNA binding for PRC2nucleosome interaction led us to hypothesize that RNA was not just inhibiting PRC2 binding to nucleosomes but, more precisely, was antagonizing PRC2 binding to protein-free linker DNA. Thus, we speculated that RNA and DNA binding are competitive. As a test, we performed fluorescence polarization competition experiments in which RNAs were titrated into reactions of preformed PRC2-(Alexa 488-dsDNA) complexes. Competitor RNA substrates were (GGAA) 10 and a negative control poly(A) 40 . In the absence of PRC2, free dsDNA gave a fluorescence polarization signal of about 55 AU (Fig. 5e) . When PRC2-dsDNA complexes were formed, the fluorescence polarization signal rose to ~170 AU. PRC2 was effectively competed from DNA using excess (GGAA) 10 RNA with a half-life of 95 ± 5 s (Fig. 5e) . Decreasing the RNA competitor concentration ten-fold did not substantially change the half-life ( Supplementary Fig. 8c) , indicating that the competitor RNA traps PRC2 upon dissociation from DNA rather than actively invading the PRC2-DNA complex. (If the competitor RNA actively invaded the PRC2-DNA complex, the measured half-life would decrease with increasing RNA concentration.) Notably, poly(A) 40 was inert and did not sequester PRC2. We also performed a gel-based competition in which RNAs were titrated into reactions of preformed PRC2-dsDNA complexes (Supplementary Fig. 8d ) and observed similar results.
Next, we reversed the competition experiment by titrating (CG) 30 competitor DNA into reactions of preformed PRC2-(Alexa 488-RNA) complexes. In the absence of PRC2, free RNA gave a fluorescence a r t i c l e s polarization signal of ~9 AU. (Fig. 5f) . When PRC2-RNA complexes were formed, the signal rose to ~80 AU. We found that 10 µM DNA competitor failed to compete PRC2 from RNA. (Notably, in the absence of tRNA competitor, the K d app values of RNA were in the picomolar range, much tighter than those measured previously in the presence of tRNA 8 ). These data collectively support the key conclusion that RNA and DNA have mutually exclusive binding to PRC2, with RNA binding with higher affinity.
JARID2 and EZH1 do not alter PRC2-nucleosome binding or RNA inhibition JARID2 and EZH1 are PRC2 components that have both been suggested to 'load' PRC2 onto nucleosomes 31 . Therefore, we hypothesized that PRC2 affinity for nucleosomes would be enhanced upon the inclusion of JARID2 or upon substitution of EZH1 for EZH2. PRC2−JARID2 6-mer and PRC2−EZH1 5-mer complexes were expressed and purified (Online Methods). In both cases, a multistep chromatography approach was used to ensure the purity of the complex, and the final size-exclusion column chromatogram showed a monodispersed peak (PRC2−JARID2 6-mer shown in Fig. 6a,b) .
We first evaluated the enzymatic properties of each protein complex using nucleosome substrates. In our HMTase assay (Fig. 6c) , the PRC2−JARID2 6-mer complex automethylated JARID2, as has been reported 22 . The JARID2 automethylation signal provided some additional evidence that our purification scheme preserved the integrity of JARID2. Furthermore, H3K27 methylation of nucleosomes by the reconstituted PRC2−JARID2 6-mer complex was improved approximately three-fold compared to that of the PRC2 5-mer complex ( Fig. 6c,d) , consistent with published studies in which JARID2 protein was titrated into PRC2-H3 reactions 5, 32 . In the case of the PRC2−EZH1 5-mer complex, the enzymatic activity was substantially (Supplementary Fig. 9a,b) , in agreement with an in vivo study that has suggested that EZH1 maintains basal H3K27 monomethylation activity 33 .
We thought that these differences in activity might foreshadow differences in nucleosome-binding activity. However, neither the PRC2−JARID2 6-mer complex nor the PRC2−EZH1 5-mer complex had differences in nucleosome binding compared to that of the typical PRC2 5-mer complex (Supplementary Fig. 9c ). In addition, both complexes showed trends similar to PRC2 5-mer in binding to RNA (Supplementary Fig. 9d ) and to DNA (Supplementary Fig. 9e ) and in RNA-mediated disruption of PRC2-nucleosome binding ( Fig. 6e  and Supplementary Fig. 10) .
DISCUSSION
Numerous studies have established the importance of PRC2 for epigenetic gene silencing in mammals and mapped the genomic sites of H3K27me3 deposition in multiple cell types. However, fundamental mechanistic questions remained. How does PRC2 bind chromatin? How is PRC2 recruited to particular sites in the genome? Does RNA binding to PRC2 regulate these events, and if so, how? Here we use quantitative biochemistry with purified PRC2 and reconstituted nucleosomes to address these questions. Although in vivo there will undoubtedly be numerous exceptions to these 'rules' established in vitro, these exceptions should stimulate the search for additional factors (for example, nonhistone chromosomal proteins or post-translational modifications) that explain why events in cells might diverge from the biochemical paradigm.
How does PRC2 bind chromatin?
Candidates for PRC2 recruitment to chromatin have included histone tails, DNA, nonhistone proteins, and RNA 1, 34, 35 . Binding of PRC2 by various N-terminal tails of histone H3 is well established and has been directly observed by means of X-ray crystallography 15, 36 . Yet, do such interactions provide sufficient binding energy, given measured affinities of histone peptide-PRC2 in the 40-400-µM range? Here we found that different histone marks make minor contributions to net PRC2 binding of nucleosomes in vitro (see below). Instead, the histone-free linker DNA has a central and direct role in the recruitment of PRC2 to an adjoining NCP, with an observed binding affinity in the nanomolar range. In the absence of an available DNA linker, such as with a nucleosome core particle, PRC2 targeting to nucleosomes is substantially weakened in vitro. The groups of Beat Fierz and Jürg Müller have also found that PRC2 binding to DNA provides the main contribution to its affinity for chromatin 37 , in agreement with our conclusion. Their use of single-molecule TIRF microscopy provides data complementary to the ensemble assays used in our study.
What in vivo data relate to our findings? ChIP-seq studies find PRC2 peaking near transcriptional start sites, which are typically nucleosome-free regions 15, 38 ; however, the resolution of current ChIP-seq data sets does not allow for a definitive comparison of PRC2 binding sites and nucleosome positioning. Nevertheless, one pioneering study has provided evidence of mutual exclusion between SUZ12 binding and nucleosome density on targeted CGIs 39 . Moreover, our biochemical findings are in agreement with a recent study that concluded that H3K27M is not involved in the recruitment or sequestration of PRC2 in vivo 40 .
Another conclusion from our investigation is that the core PRC2 complex (EZH2−EED−SUZ12) has robust DNA-binding activity. This offers an alternative perspective to the standing assumption that core PRC2 subunits lack the ability to bind DNA 41 . Because DNA and RNA binding are competitive, the implication is that the same core PRC2 components that bind RNA 8 also possess intrinsic DNA-binding activity through still-uncharacterized domains. a r t i c l e s Thus, our new perspective is that nucleosome-free regions of chromatin and nucleosome linkers recruit PRC2, after which it will bind histone tails in its vicinity. PRC2 HMTase will then be stimulated by existing H3K27me3 or repressed by binding H3K4me3, as in the canonical model. Inherent to this new model is that PRC2 enrichment at a target site can be explained by chromatin binding in hierarchical fashion, with nanomolar affinity DNA-binding components cooperating with micromolar affinity histone-tail-binding modules. This engagement with histone tails might reorient the enzyme on chromatin, leading to activation of HMTase activity or inhibition in the case of H3K27M. Conceivably, there might be an offsetting energetic penalty associated with simultaneous engagement of PRC2 with DNA and histone tails, explaining why the net effect of H3K27M on overall binding is observed to be modest (lower than simple binding additivity would predict).
What defines a gene target for PRC2-mediated epigenetic silencing?
In search of a recruiting DNA element, our in vitro analysis showed that PRC2 prefers binding to CG-rich sequences. This finding is consistent with multiple studies showing that PRC2 target genes contain CG-rich sequences in vivo 8, 17, 27, 42 . Past studies have also proposed that CGIs could be novel recruiters for PRC2 in mammals. Interestingly, CGIs and CG content have been shown to be key factors that promote nucleosome instability and depletion 43, 44 ; this may further contribute to PRC2 binding CG-rich regions in vivo.
Our finding that PRC2 5-mer complexes have an intrinsic preference for mCpG DNA is surprising, given that genome-wide data suggest cytosine methylation antagonizes PRC2 binding 35, [45] [46] [47] . On the other hand, PRC2 has been suggested to be directly associated with DNA methylation, and loss of DNA methylation can lead to loss of H3K27me3 and PRC2, in agreement with our in vitro results showing that methylated DNA binds optimally 48, 49 . The discrepancy between the various studies could come from different compositions of PRC2 subcomplexes. We have found that the AEBP2 subunit of PRC2 acts as an effector of specificity for methylated DNA. PRC2 complexes lacking AEBP2 bind DNA with low nanomolar affinity, regardless of CpG methylation status. The incorporation of AEBP2 into the PRC2 complex reconfigures the binding properties of PRC2 to greatly reduce its affinity for unmethylated DNA. The targeting to methylated DNA by AEBP2 is dependent on its C2H2 zinc-finger domains. In fact, one recent study reports that AEBP2 plays a role in defining the mutually exclusive composition of PRC2 subcomplexes 50 . AEBP2 is not the only epigenetic regulator that associates with the PRC2 core complex. Indeed, other accessory subunits in PRC2 subcomplexes may promote exclusion from methylated CGIs, and mCpG-binding proteins could in some cases hide mCpG from PRC2. Future studies are needed to test such hypotheses.
Drosophila has PREs, which recruit proteins such as PHO and other DNA-binding factors 51, 52 . Such factors then recruit Drosophila PRC2 (dPRC2) in hierarchical fashion. Even though the PRC2  5m   24 12  6  3  24 12  6  3  24 12  6  3  24 a r t i c l e s sequence specificity of dPRC2 for PREs is not fully understood, this DNA-based recruitment mechanism is widely accepted. In mammals, no homologs of PREs or orthologs of the dPRC2-recruiting proteins have been identified 53 . However, our study demonstrates that human PRC2 has robust DNA-binding activity (with nanomolar K d app ). In addition, nucleosome-kinetic studies have suggested that PREs are areas of histone replacement and reduced nucleosome occupancy 54 .
Our findings indicate that the intrinsic DNA-binding activity of human PRC2 is important for binding to chromatin and promoting activity. Therefore, PRC2 recruitment in mammals and Drosophila may be more similar than previously thought.
JARID2
JARID2 has been identified and recognized as an important regulator of PRC2. Initial studies concluded that JARID2 negatively regulates PRC2 activity, but subsequent studies have reported that JARID2 is an activator 55, 56 . This contradiction could simply arise from different substrates used in activity assays (for example, unfolded histone H3 versus histone octamer versus nucleosome), or it could be due to difficulties during protein purification 5 . We reconstituted the PRC2−JARID2 6-mer complex by coexpressing JARID2 with the other five subunits, and we then used well-assembled nucleosomes as our substrate in activity assays. We found that the incorporation of JARID2 substantially stimulates EZH2 catalytic activity, as indicated by an increase in H3K27 methylation and EZH2 automethylation. This finding supports the conclusion that JARID2 may allosterically regulate PRC2, in agreement with previous findings from mixing experiments using PRC2 and JARID2 (refs. 5,31). However, we did not observe increased nucleosome-binding affinity, as a previous study suggested 31 . This discrepancy could be due to the previous use of truncated JARID2 proteins to test nucleosome-binding affinity, rather than full-length JARID2 in complex with PRC2 as used here. Furthermore, although JARID2 has been proposed to have an N-terminal noncoding RNA-binding region 57 , we found that the inclusion of JARID2 did not alter PRC2 RNA-binding activity (Supplementary Fig. 9d ). However, our RNA cross-linking analysis showed that JARID2 may contribute a surface that contacts RNA when it is in complex with PRC2 ( Supplementary Fig. 9f,g) .
How does RNA binding regulate PRC2?
Why is the PRC2 gene-silencing complex recruited to actively transcribed genes? Why doesn't PRC2 suppress transcriptional activity at those genes when bound? These perplexing observations can now be explained by the intrinsic properties of PRC2-RNA-nucleosome interactions. In highly expressed genes, PRC2 may be bound by RNA emerging from active genes, but it is not able to promote silencing, because the RNA shuttles PRC2 away from chromatin. RNA inhibition of PRC2-chromatin binding was previously observed in nonequilibrium pulldown assays 10 . Our work now provides an unexpectedly simple mechanism for this eviction: (1) RNA and DNA bind PRC2 competitively, with RNA having higher affinity. (2) DNA binding is necessary for PRC2 to bind nucleosomes. (3) Thus, PRC2 cannot bind nucleosomes in the presence of a saturating amount of RNA. Furthermore, these results provide mechanistic understanding for how RNA can hold PRC2 poised but in check 5 . RNA is not an active-site inhibitor of PRC2 methyltransferase activity, as evidenced by the unperturbed automethylation activity, but instead prevents PRC2 from binding its nucleosome substrate.
In conclusion PRC2 recruitment to target sites is perhaps one of the most enigmatic aspects of its function. As a gene silencer with an intrinsic ability to propagate its own heritable enzymatic product, PRC2 must possess a repertoire of biochemical properties suitable to its biological function. Together, our findings reveal new insights into how PRC2 associates with nucleosomes and on the interplay of PRC2 binding to chromatin and RNA. a r t i c l e s RNA >> nucleosomes with linker DNA ≈ DNA >> histone tails (Fig. 7a,b) . Based on these relative affinities, as well as the passive role of RNA in dissociating PRC2-nucleosome complexes, we propose the following model ( Fig. 7c) : the PRC2 complex is recruited to target genes by binding to DNA, with contributions in specificity conferred by CG-rich sequences or CGIs. This DNA binding by PRC2 could promote scanning of nearby chromatin and the recognition of histone marks. Most of the affinity of PRC2 binding comes from its binding to DNA, not histones; its binding to histone tails is of course necessary for H3K27-trimethylation and for regulation, but it makes a minor contribution to affinity. In the case of active transcription units, on the other hand, the nascent pre-mRNA or nearby lncRNA transcripts bind PRC2 and prevent its deposition to chromatin; thus, the active state is maintained. These models will no doubt prove to be oversimplified in particular biological situations in which the presence of other proteins or ribonucleoproteins (either PRC2 bound or chromatin bound) may overcome or compete with the intrinsic properties of the PRC2 complex. Yet understanding the fundamental properties of the PRC2-nucleosome interaction provides a framework for interpretation of specific instances where epigenetic gene silencing is maintained or is switched on or off.
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